A groundbreaking investigation has illuminated a significant and concerning link between obesity and the accelerated progression of Alzheimer’s disease, as evidenced by changes in specific blood markers. Researchers have reported that individuals classified as obese exhibited a substantially faster rise in Alzheimer’s disease blood biomarkers (BBMs) – in some instances, up to 95% more rapidly – compared to their non-obese counterparts. These compelling findings were presented at the esteemed annual meeting of the Radiological Society of North America (RSNA), marking a pivotal moment in understanding the complex interplay between metabolic health and neurodegenerative disease.
This pioneering study represents the first documented instance of directly correlating obesity with Alzheimer’s disease progression as measured through the analysis of blood biomarkers. "This is the first time we’ve shown the relationship between obesity and Alzheimer’s disease as measured by blood biomarker tests," stated Dr. Cyrus Raji, a senior author on the study and a principal investigator within the Neuroimaging Labs Research Center at the Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis. His commentary underscores the novelty and significance of these findings in the ongoing quest to unravel the multifaceted nature of Alzheimer’s disease.
To meticulously explore this intricate connection, the research team harnessed a comprehensive five-year dataset derived from 407 volunteers participating in the Alzheimer’s Disease Neuroimaging Initiative. This extensive longitudinal study provided an invaluable dual source of information: detailed amyloid positron emission tomography (PET) scans of participants’ brains and meticulously collected blood samples. PET scans are an advanced neuroimaging technique crucial for visualizing and quantifying the extent of amyloid burden in the brain. This burden refers to the accumulation of beta-amyloid protein, which aggregates into amyloid plaques, a hallmark pathological feature of Alzheimer’s disease and a key indicator of its progression.
The researchers meticulously analyzed plasma samples for a panel of BBMs critically associated with Alzheimer’s disease. This included levels of phosphorylated tau protein at threonine 217 (pTau217), a biomarker increasingly recognized for its diagnostic and monitoring utility in Alzheimer’s disease. Also examined was neurofilament light chain (NfL), a protein fragment released into the bloodstream when neurons are damaged or undergoing degeneration, serving as an indicator of neuronal injury. Furthermore, plasma glial fibrillary acidic protein (GFAP) was measured; GFAP is a protein predominantly expressed by astrocytes, the star-shaped glial cells that provide essential support and protection to neurons within the brain and spinal cord. These analyses were conducted using six leading commercially available diagnostic tests, ensuring a robust and reliable assessment of the selected biomarkers.
Employing sophisticated statistical methodologies, the research team rigorously examined the relationships between these BBMs and body mass index (BMI), a standard measure of body fat relative to height. They specifically evaluated a three-way interaction effect involving baseline obesity status, the passage of time, and the observed changes in BBMs. To further validate their findings, the researchers cross-referenced and confirmed the BBM results against the independent data obtained from the amyloid PET scans, thereby strengthening the overall credibility of their conclusions.
An initial intriguing observation emerged when combining the blood and imaging data: at the commencement of the study, individuals with a higher BMI exhibited lower baseline levels of certain BBMs and a comparatively lower overall amyloid burden across their brains. Dr. Soheil Mohammadi, the study’s lead author and a postdoctoral research associate at MIR, offered a compelling explanation for this initial discrepancy. "We believe the reduced BBMs in obese individuals was due to dilution from the higher blood volume," he explained. "In fact, by relying on the baseline measurements, you could be fooled into thinking that the people with obesity had a lower pathology of Alzheimer’s disease. We need the longitudinal data to fully understand the how obesity impacts the development of Alzheimer’s pathology." This highlights the critical importance of longitudinal study designs, which involve repeatedly collecting data from the same individuals over extended periods, allowing for the tracking of dynamic changes and trends that might otherwise be obscured by single-point measurements.
The longitudinal data collected over the five-year period provided the crucial insights that challenged initial assumptions. As time progressed, both the Alzheimer’s disease BBMs and the brain PET scans revealed a significantly greater accumulation of Alzheimer’s-related pathology in participants who were obese at the study’s outset, in stark contrast to those who were not. Specifically, individuals with obesity demonstrated a 29% to 95% accelerated increase in plasma pTau217 ratio levels. Furthermore, the presence of obesity at baseline was associated with a 24% faster rise in plasma NfL, indicating more rapid neuronal damage, and a 3.7% more rapid increase in amyloid accumulation within the brain.
Dr. Raji further emphasized the remarkable sensitivity of blood tests in this context. "The fact that we can track the predictive influence of obesity on rising blood biomarkers more sensitively than PET is what astonished me in this study," he remarked. This suggests that blood-based biomarkers may offer a more accessible and potentially earlier window into the impact of obesity on Alzheimer’s pathology than traditional imaging techniques, which are often more costly and less readily available.
The clinical implications of these findings are profound and underscore the critical role of modifiable risk factors in Alzheimer’s disease management. Dr. Mohammadi elaborated on how obesity’s influence on the progression of amyloid burden and subsequent shifts in blood biomarkers carries significant weight for clinicians assessing and managing an individual’s risk for Alzheimer’s. He referenced the 2024 report from The Lancet Commission, which identified a total of 14 modifiable risk factors that collectively account for approximately 45%, or nearly half, of the overall risk for developing Alzheimer’s disease. "If we can reduce any of those risk factors, we can significantly reduce Alzheimer’s cases or lengthen the amount of time until the onset of the disease," he asserted, highlighting the actionable nature of this research.
Looking ahead, Dr. Raji expressed anticipation for the future of brain health monitoring and therapeutic interventions. He foresees a growing integration of repeated blood biomarker measurements, coupled with brain imaging, as a standard practice for tracking the effectiveness of treatment strategies, particularly those involving novel anti-amyloid drugs. "This is such profound science to follow right now because we have drugs that can treat obesity quite powerfully, which means we could track the effect of weight loss drugs on Alzheimer’s biomarkers in future studies," he posited. This opens up exciting avenues for research, allowing scientists to investigate the potential benefits of weight management interventions on Alzheimer’s pathology through the lens of these sensitive blood markers. "It’s marvelous that we have these blood biomarkers to track the molecular pathology of Alzheimer’s disease, and MRI scans to track additional evidence of brain degeneration and response to various treatments," Dr. Raji concluded. "This work is foundational for future studies and treatment trials." The study was also co-authored by Farzaneh Rahmani, M.D., M.P.H., Mahsa Dolatshahi, M.D., M.P.H., and Suzanne E. Schindler, M.D., Ph.D., who contributed significantly to this comprehensive research effort.
About the Author
